Phase II evaluation of EMD121974 (NSC 707544, cilengitide) in asymptomatic patients with metastatic androgen independent prostate cancer.

Trial Profile

Phase II evaluation of EMD121974 (NSC 707544, cilengitide) in asymptomatic patients with metastatic androgen independent prostate cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2013

At a glance

  • Drugs Cilengitide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jul 2012 Actual end date (1 Jan 2011) added as reported by CliniclaTrials.gov.
    • 01 Jan 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top